There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small ...

For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

Bob Uecker's cause of death has not been revealed, but his family said he had been battling small cell lung cancer since early 2023.

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

For early-stage NSCLC, lobar resection has been the gold standard since 1995 with publication of the LCSG trial. Given that ...

Prognosis refers to the expected trajectory and outcome of a disease. The prognosis of non-small cell lung cancer varies depending on the specific subtype and the stage of cancer at diagnosis.